ALC241220C50000
- 0.00
- 0.000.00%
Alcon Newsroom
Impressive Earnings May Not Tell The Whole Story For Alcon (VTX:ALC)
Deutsche Bank Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $92.9
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Orbis International Brings the Flying Eye Hospital to Bangladesh to Improve Eye Care
J.P. Morgan Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $89.5
Analysts Conflicted on These Healthcare Names: Alcon (ALC), Innate Pharma SA (OtherIPHYF) and ScPharmaceuticals (SCPH)
BofA Securities Maintains Alcon(ALC.US) With Hold Rating, Cuts Target Price to $93.63
Jefferies Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $100
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $93.63 to $107
KeyBanc Sticks to Their Buy Rating for Alcon (ALC)
Alcon's Strong Market Position and Growth Prospects Underscore Buy Rating
Express News | Alcon AG : Jefferies Cuts Target Price to $100 From $105
Alcon (ALC) Q3 2024 Earnings Call Transcript Summary
Swiss Stocks Close Little Changed; SoftwareOne Jumps on Upbeat Revenue Outlook
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $97.06 to $107
Alcon's Mixed Q3 Performance and Product Pipeline Drive Hold Rating
Alcon Analyst Ratings
Alcon Down 6%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View